title: Auxiliary Partial Orthotopic Living Liver Transplant for Wilson Disease.
abstract: Wilson disease is a genetic disease involving copper metabolism disturbances that result in copper accumulations, especially in the liver and brain. Wilson disease can be treated with pharmacologic agents, such as chelators that induce urinary excretion of copper or zinc salts that inhibit copper absorption in the digestive tract. Liver transplant is the only treatment option for Wilson disease when liver failure has occurred. In some patients, that is, in those with Child-Pugh A score, neurologic disease can be seen without hepatic failure. Our recommendation is for these patients to have auxiliary partial orthotopic liver transplant. Here, we present a 36-year-old male patient with neurologic disease associated with Wilson disease who had successful related living-donor auxiliary partial orthotopic liver transplant using a left lobe. The patient, as a result of neurologic symptoms that included tremor walking and speaking problems and low serum ceruloplasmin level of 7 mg/dL, was diagnosed with Wilson disease, and a liver biopsy was performed. Chronic necroinflammatory disease activity was 4/18, and the patient received chelation treatment. His hepatic functions were normal. The donor was the patient's 57-year-old father whose liver function tests were also normal. The graft-to-recipient weight ratio was 1% using a left lobe graft. After transplant, serum ceruloplasmin levels on day 15 and month 1 were 14 and 19 mg/dL. At month 1, liver function tests were normal. Doppler ultrasonography showed normal vascular flow of the native liver and the graft. The patient's neurologic symptoms were progressively reduced. Progressive neurologic deterioration with no hepatic insufficiency is considered a suitable indication for auxiliary partial orthotopic liver transplant; this procedure is suggested before the neurologic and liver failure symptoms of Wilson disease occur.
authors.affiliation: Department of General Surgery and Transplantation, Baskent University, Ankara, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Haberal
authors.forename: Aydincan
authors.initials: A
authors.lastname: Akdur
authors.forename: Gokhan
authors.initials: G
authors.lastname: Moray
authors.forename: Sedat
authors.initials: S
authors.lastname: Boyacioglu
authors.forename: Adnan
authors.initials: A
authors.lastname: Torgay
authors.forename: Gulnaz
authors.initials: G
authors.lastname: Arslan
authors.forename: Gulnaz
authors.initials: G
authors.lastname: Arslan
authors.forename: Binnaz Handan
authors.initials: BH
authors.lastname: Ozdemir
mesh_terms: D000328:Adult; D002614:Chelating Agents / Q000627:therapeutic use; D002760:Cholangiopancreatography, Endoscopic Retrograde; D058625:End Stage Liver Disease / Q000175:diagnosis / Q000209:etiology / Q000601:surgery*; D005220:Fathers; D006527:Hepatolenticular Degeneration / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D002614:Chelating Agents